MSB News: Mesoblast's (MESO) GVHD Drug BLA Gets FDA Priority Tag, Stock Up - 9th Mar 2023, 10:58pm

[annb0t]

Melbourne-based biotech, Mesoblast Limited MESO announced the FDA acceptance of the resubmission of its biological license application (BLA) for remestemcel-L for the treatment of pediatric steroid-refractory acute graft versus host disease (SR-aGVHD). The FDA considered the resubmission of a complete response and granted priority review designation to the BLA. The FDA’s decision is expected on Aug 2, 2023. Shares of the company were up 24% on Wednesday, following the news.

In the past yea...

>>> Read more: Mesoblast's (MESO) GVHD Drug BLA Gets FDA Priority Tag, Stock Up